Substantial Equivalence of iSlpr™ and SomnoDent® Classic in the Treatment of Snoring and Mild to Moderate Sleep Apnoea.

NCT ID: NCT04250584

Last Updated: 2020-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-31

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a thirty three week, prospective, open-label, randomized, parallel-group non-inferiority study.

The study aims to investigate the Substantial Equivalence of a novel mandibular device called iSlpr™, produced by BioAnalytics, to a currently approved device, SomnoDent® Classic, in the treatment of mild to moderate Obstructive Sleep Apnoea (OSA) and snoring.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to determine if the BioAnalytics device, iSlpr™, has a similar safety and efficacy profile to a commonly used device, SomnoDent® Classic, in the treatment of snoring and mild to moderate Obstructive Sleep Apnoea.

The target population will be males and females aged from 18 years to less than 75 years, who have been diagnosed with snoring and mild to moderate sleep apnoea.

Participants will remain on study from screening visit to end of study visit; a total of approximately 33 weeks.

This study includes -

* a screening period of up to 28 days
* a 2 week device initiation period
* a 24 week treatment period

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Apnea Snoring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Device

Novel Mandibular Advancement Device

Group Type EXPERIMENTAL

iSlpr™

Intervention Type DEVICE

mandibular advancement device

Predicate Device

Predicate Mandibular Advancement Device

Group Type ACTIVE_COMPARATOR

SomnoDent® Classic

Intervention Type DEVICE

mandibular advancement device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iSlpr™

mandibular advancement device

Intervention Type DEVICE

SomnoDent® Classic

mandibular advancement device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older and younger than 75 years at time of screening
* Snoring and mild to moderate sleep apnoea ( AHI \> 5 and \< 30 per hr)
* Written informed consent
* Able to complete the study procedures within the study timeline.

Exclusion Criteria

* Women who are pregnant or breast-feeding
* Central sleep apnoea
* Severe respiratory disorders
* Loose teeth or advanced periodontal disease
* Lateral bruxers
* Full or partial dentures
* Temporomandibular Joint (TMJ) abnormalities, pain or dysfunction
* Other teeth, jaw or gum disorders would preclude use of the device
* Cardiovascular comorbidities or stroke/heart attack in past 12 months
* Drug-addiction
* Major Depressive Disorder or psychosis
* Undergoing concomitant therapy for OSA/Snoring
* current or previous therapy with SomnoDent Classic
* Professional drivers or machine operators required to be undertaking CPAP
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioAnalytics Holdings Pty Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cyril Jones

Role: CONTACT

Phone: +61 419 594 572

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BAH001

Identifier Type: -

Identifier Source: org_study_id